ClinicalTrials.Veeva

Menu

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Amgen logo

Amgen

Status and phase

Completed
Phase 3

Conditions

Prostate Cancer

Treatments

Drug: Placebo
Drug: AMG 162

Study type

Interventional

Funder types

Industry

Identifiers

NCT00089674
20040138
HALT Prostate Cancer

Details and patient eligibility

About

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Enrollment

1,468 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Other criteria also apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

1,468 participants in 2 patient groups, including a placebo group

AMG 162
Experimental group
Treatment:
Drug: AMG 162
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems